NCT01560585终止1 期
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Change From Baseline to Six Month Timepoint in the Score on the Alzheimer's Disease Assessment Scale- Cognitive Subscale
研究概览
简要总结
This is an open label study of isotretinoin, a medication which is FDA approved for treatment of other conditions to determine initial safety in Alzheimer's disease.
详细描述
Retinoids have some relevant characteristics that could be considered useful in treating AlZheimer's disease. These include anti-inflammatory properties, possible anti-amyloid formation proeprties and inhibition of cell cycle properties
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
"open label study" before being prematurely terminated
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Probable AD by DSM IV and NINCDS-ADRDA criteria
- •Females must be surgically sterile (bilateral tubal ligation, both ovaries removed or hysterectomy) or post-menopausal for at least 2 years.
- •> 50 years of age
- •Residing in the community at baseline (includes assisted living facilities, long-term care nursing facilities)
- •Mini Mental State Examination at screen of 12-26 (inclusive)
- •No medical contraindications to study participation
- •Fluent in English at least 8 years of education.
- •Supervision available for study medication. Caregiver/study partner to accompany participant to all visits. Study partner must have direct contact with the participant > 2 days/week
- •Able to ingest oral medication.
- •Neuroimaging (CT or MRI or PET) consistent with the diagnosis of AD at some time after the onset of the memory decline.
- •Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the investigator
- •Stable use of cholinesterase inhibitors and memantine is permitted if doses are stable for 3 months prior to enrollment. Dose should be stable throughout the study unless it is clinically necessary to adjust the medication.
- •Stable use of anti-depressants is permitted if doses are stable for 3 months prior to enrollment. Dose should be stable throughout the study unless it is clinically necessary to adjust the medication.
排除标准
- •Dementia not due to probable Alzheimer's disease
- •Pregnancy, breastfeeding. The rationale is that retinoids are teratogenic and are excreted in breast milk.
- •History of clinically significant stroke
- •Modified Hachinski Ischemia score ≥ 4
- •Current evidence or history in past two years of epilepsy, seizure, focal brain lesion, head injury with loss of consciousness or DSM IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, severe alcohol or substance abuse.
- •Sensory impairment which would prevent subject from participating in or cooperating with the protocol.
- •Use of another investigational agent within two months.
- •Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational new drug including clinically significant or unstable hematologic, hepatic, cardiovascular (including history of ventricular fibrillation or ventricular tachycardia), pulmonary, gastrointestinal, endocrine, metabolic, renal, or other systemic disease or laboratory abnormality. Abnormal liver function test, including AST, ALT, total bilirubin, or prothrombin time. The rationale is that retinoids can be hepatotoxic.
- •Participants receiving behavioral medications (including antidepressants, antipsychotics and anxiolytics) must be on stable doses for at least 4 weeks prior to randomization.
- •Active neoplastic disease and any medical conditions requiring concurrent immunosuppression.
- •Hypertriglyceridemia greater than 500 mg/dL despite statin/fibrate therapy. The rationale is that retinoids can increase lipids, particularly triglyceride and this can lead to pancreatitis.
- •Any medical conditions requiring concurrent use of tetracycline, minocycline, or doxycycline. The rationale is due to enhanced risk of increased intracranial pressure.
- •Hypersensitivity to retinoids.
- •Presence of psychosis or hallucinations at baseline as determined by Neuropsychiatric inventory or Geriatric Depression Scale-short form greater than or equal to five
- •Presence of any unstable cardiovascular disease, uncontrolled diabetes, chronic inflammatory or infectious conditions. Retinoids have been associated with chest pain of unclear etiology, increased serum glucose, myelosuppression and increased risk of infection.
- •Use of Drugs and supplements such as: Vitamin A supplements beyond 100% RDA, other immunosuppressants (corticosteroids, chemotherapeutic agents, etc.), Warfarin , Fish Oil (DHA)
- •Any other disease or medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this clinical trial.
研究组 & 干预措施
Open label
Experimental
All participants will receive Isotretinoin for 24 weeks
干预措施: Isotretinoin (Drug)
结局指标
主要结局
Change From Baseline to Six Month Timepoint in the Score on the Alzheimer's Disease Assessment Scale- Cognitive Subscale
时间窗: 6 months from baseline
Alzheimer's disease Assessment Scale- Cognitive subscale is a scale to measure cognitive function used in dementia clinical trials. No primary outcome data since study was terminated before any participaant completed
次要结局
- Number of Adverse Effects(28 weeks)
研究者
Alan Lerner, MD
Director, Brain Health and Memory Center, Neurological Institute
University Hospitals Cleveland Medical Center
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic DermatitisAtopic DermatitisNCT03553615Stanford University
已完成
3 期
Treatment of Patients With Nephrogenic Systemic Fibrosis With GlivecNephrogenic Systemic FibrosisNCT00981942University of Aarhus10
已完成
2 期
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-TProstate CancerNCT01174368The Rogosin Institute1
已完成
1 期
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid TumorsAdvanced Solid TumorNCT05043298Innovent Biologics (Suzhou) Co. Ltd.12
撤回
早期 1 期
A Study of RD06-04 in Patients With Active Autoimmune DiseasesSclerosisANCA Associated VasculitisIIMNMO Spectrum DisorderSSMSMGNCT06548620Nanjing Bioheng Biotech Co., Ltd.18